Find the Right Market Report

Search thousands of industry reports, market insights, and research studies in one place.

Not sure where to start? Try one of these:
Explore healthcare market intelligence and industry insights
Towards Healthcare

Capivasertib Corporate Milestones

Date : 19 May 2026

Companies Offerings in the Capivasertib Market

Capivasertib Market Companies are AstraZeneca, Astex Therapeutics, MSD, Daiichi Sankyo, The Institute of Cancer Research, Cancer Research

Companies Description
AstraZeneca It has rolled out Truqap, a first-in-class, oral AKT inhibitor.
Astex Therapeutics Its offerings cover discovery platforms, commercial agreements, etc.
MSD This firm facilitated an oncology alliance with AstraZeneca to co-develop drugs, including Lynparza & Koselugo.
Daiichi Sankyo A company explores clinical synergies between capivasertib & their own antibody-drug conjugate (ADC) portfolio, especially in breast cancer.
The Institute of Cancer Research This mainly acts as a foundational role in discovering & designing capivasertib.
Cancer Research Technology Limited This provides discovery & synthesis, structure-based designing, preclinical testing, & early clinical development solutions for oncology drugs.
Sun Pharmaceutical Industries Ltd. This company offers clinical research & advanced cancer care.
Novartis A firm provides drugs acting through the AKT pathway inhibition.
Gilead Sciences, Inc. It facilitates diverse Trop-2-directed antibody-drug conjugates & cell therapies.
Eisai Co., Ltd. This is mainly providing its clinical evaluation & regulatory framework within Japan, specifically in combination with other therapies for breast cancer.

What are the Revolutionary Developments in the Capivasertib Market?

  • In April 2026, the US FDA Oncologic Drugs Advisory Committee (ODAC) recommended AstraZeneca’s TRUQAP (capivasertib) in combination with abiraterone & androgen deprivation therapy (ADT) for the treatment of patients with PTEN-deficient metastatic hormone-sensitive prostate cancer (mHSPC).
  • In September 2025, Riken Genesis Co., Ltd. & Burning Rock Biotech Limited launched the OncoGuide OncoScreen Plus CDx System as a companion diagnostic for AstraZeneca’s capivasertib.

Capivasertib Market- Supply Chain Analysis

R&D

  • Many leading companies are following fundamental structural biology, fragment-based drug designing, improvement to avoid cardiac toxicity, & strong clinical trials emphasizing AKT inhibition.
  • Key Players: AstraZeneca, Astex Therapeutics, the Institute of Cancer Research (ICR), etc.

Clinical Trials & Regulatory Approvals

  • Firms are demonstrating from preclinical studies through Phase I-III trials, along with combination therapy. Further, firms follow fast-track review based on Phase 3 trial data, guided by a companion diagnostic test approval.
  • Key Players: West German Study Group, Relay Therapeutics, Inc., VA Office of Research and Development, etc

Patient Support & Services

  • Specifically, the MyTRUQAP Support Program provides co-pay assistance, educational resources, & insurance coverage guidance
  • Key Players: Alleviare India, AstraZeneca, MitoGENE, etc.

Market Growth

The global capivasertib market size was estimated at USD 485.7 million in 2025 and is predicted to increase from USD 584.78 million in 2026 to approximately USD 3109.09 million by 2035, expanding at a CAGR of 21.05% from 2026 to 2035.

Capivasertib Market Size is USD 584.78 Million in 2026.

Ready to make better
healthcare business decisions?

Speak with a healthcare analyst about your research, consulting, or platform needs.

Talk to an Analyst Contact Sales